cHL-话题@MedSci - 梅斯（MedSci）

#cHL#

16篇内容 | 1018人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1985312, encodeId=269419853122c, content=<a href='/topic/show?id=186046636e' target=_blank style='color:#2F92EE;'>#cHL#</a>, objectTitle=Eur J Cancer：GLS-010 (zimberelimab)在中国复发或难治性经典霍奇金淋巴瘤(r/r-cHL)患者中的疗效和安全性, objectType=article, longId=220097, objectId=8a2422009e45, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a2422009e45, replyNumber=0, likeNumber=67, createdTime=2022-07-18, rootId=0, userName=12498adam40暂无昵称, userId=f07c2500133, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a2422009e45, moduleTitle=Eur J Cancer：GLS-010 (zimberelimab)在中国复发或难治性经典霍奇金淋巴瘤(r/r-cHL)患者中的疗效和安全性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=8a2422009e45)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985311, encodeId=6d7a1985311ab, content=<a href='/topic/show?id=186046636e' target=_blank style='color:#2F92EE;'>#cHL#</a>, objectTitle=Clin Cancer Res：Tislelizumab（替雷利珠单抗）治疗复发/难治性经典霍奇金淋巴瘤(cHL)患者疗效和安全性。, objectType=article, longId=220072, objectId=4ff72200e20b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ff72200e20b, replyNumber=0, likeNumber=71, createdTime=2022-06-26, rootId=0, userName=12498adam40暂无昵称, userId=f07c2500133, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ff72200e20b, moduleTitle=Clin Cancer Res：Tislelizumab（替雷利珠单抗）治疗复发/难治性经典霍奇金淋巴瘤(cHL)患者疗效和安全性。, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4ff72200e20b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985310, encodeId=684e1985310d0, content=<a href='/topic/show?id=186046636e' target=_blank style='color:#2F92EE;'>#cHL#</a>, objectTitle=Cochlear Implants Int：Baha®的听觉益处和性能改善吸引了单侧听力损失患者的植入, objectType=article, longId=209300, objectId=f06b20930086, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f06b20930086, replyNumber=0, likeNumber=73, createdTime=2021-04-26, rootId=0, userName=12498adam40暂无昵称, userId=f07c2500133, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f06b20930086, moduleTitle=Cochlear Implants Int：Baha®的听觉益处和性能改善吸引了单侧听力损失患者的植入, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f06b20930086)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985309, encodeId=79ae1985309fd, content=<a href='/topic/show?id=186046636e' target=_blank style='color:#2F92EE;'>#cHL#</a>, objectTitle=FDA批准默克的KEYTRUDA（派姆单抗），治疗复发或难治性经典霍奇金淋巴瘤（cHL）成年患者, objectType=article, longId=202168, objectId=22ff2021685a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22ff2021685a, replyNumber=0, likeNumber=77, createdTime=2021-04-18, rootId=0, userName=12498adam40暂无昵称, userId=f07c2500133, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22ff2021685a, moduleTitle=FDA批准默克的KEYTRUDA（派姆单抗），治疗复发或难治性经典霍奇金淋巴瘤（cHL）成年患者, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=22ff2021685a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985305, encodeId=302a1985305c1, content=<a href='/topic/show?id=186046636e' target=_blank style='color:#2F92EE;'>#cHL#</a>, objectTitle=Blood：派姆单抗单药治疗RRcHL可获得持久的缓解, objectType=article, longId=177653, objectId=fb891e765330, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb891e765330, replyNumber=0, likeNumber=84, createdTime=2019-10-20, rootId=0, userName=12498adam40暂无昵称, userId=f07c2500133, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb891e765330, moduleTitle=Blood：派姆单抗单药治疗RRcHL可获得持久的缓解, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fb891e765330)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985307, encodeId=55c1198530ee3, content=<a href='/topic/show?id=186046636e' target=_blank style='color:#2F92EE;'>#cHL#</a>, objectTitle=Neural Regen Res：Schlager小鼠可作为视网膜表型改变的模型, objectType=article, longId=189448, objectId=3cd81894483f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3cd81894483f, replyNumber=0, likeNumber=61, createdTime=2020-09-02, rootId=0, userName=12498adam40暂无昵称, userId=f07c2500133, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3cd81894483f, moduleTitle=Neural Regen Res：Schlager小鼠可作为视网膜表型改变的模型, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3cd81894483f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985308, encodeId=2ba1198530871, content=<a href='/topic/show?id=186046636e' target=_blank style='color:#2F92EE;'>#cHL#</a>, objectTitle=Cochlear Implants Int：青少年人工耳蜗使用者的健康相关生活质量研究 , objectType=article, longId=190259, objectId=9d05190259a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d05190259a3, replyNumber=0, likeNumber=77, createdTime=2020-07-10, rootId=0, userName=12498adam40暂无昵称, userId=f07c2500133, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d05190259a3, moduleTitle=Cochlear Implants Int：青少年人工耳蜗使用者的健康相关生活质量研究 , moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=9d05190259a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985306, encodeId=f3251985306dc, content=<a href='/topic/show?id=186046636e' target=_blank style='color:#2F92EE;'>#cHL#</a>, objectTitle=Blood：阻断CTLA-4或可成为对阻断PD-1耐受的cHL患者的新治疗方向, objectType=article, longId=181194, objectId=6f421811940c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f421811940c, replyNumber=0, likeNumber=74, createdTime=2020-01-19, rootId=0, userName=12498adam40暂无昵称, userId=f07c2500133, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f421811940c, moduleTitle=Blood：阻断CTLA-4或可成为对阻断PD-1耐受的cHL患者的新治疗方向, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6f421811940c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985304, encodeId=88c81985304ce, content=<a href='/topic/show?id=186046636e' target=_blank style='color:#2F92EE;'>#cHL#</a>, objectTitle=PNAS：UCHL1影响脑缺血后的损伤和功能恢复, objectType=article, longId=160142, objectId=00b6160142aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00b6160142aa, replyNumber=0, likeNumber=75, createdTime=2019-09-11, rootId=0, userName=12498adam40暂无昵称, userId=f07c2500133, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00b6160142aa, moduleTitle=PNAS：UCHL1影响脑缺血后的损伤和功能恢复, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=00b6160142aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985303, encodeId=ca1719853030b, content=<a href='/topic/show?id=186046636e' target=_blank style='color:#2F92EE;'>#cHL#</a>, objectTitle=Lancet Haematology：重磅！中国PD-1抑制剂信迪利单抗治疗cHL关键研究荣登《柳叶刀血液病学》封面, objectType=article, longId=157428, objectId=9bed15e428fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9bed15e428fb, replyNumber=0, likeNumber=73, createdTime=2019-05-04, rootId=0, userName=12498adam40暂无昵称, userId=f07c2500133, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9bed15e428fb, moduleTitle=Lancet Haematology：重磅！中国PD-1抑制剂信迪利单抗治疗cHL关键研究荣登《柳叶刀血液病学》封面, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=9bed15e428fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985302, encodeId=736a1985302cb, content=<a href='/topic/show?id=186046636e' target=_blank style='color:#2F92EE;'>#cHL#</a>, objectTitle=PD-1抑制剂替雷利珠单抗（Tislelizumab）重拳出击，在复发/难治cHL中疗效突出, objectType=article, longId=154852, objectId=fae615485275, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fae615485275, replyNumber=0, likeNumber=105, createdTime=2019-04-29, rootId=0, userName=12498adam40暂无昵称, userId=f07c2500133, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fae615485275, moduleTitle=PD-1抑制剂替雷利珠单抗（Tislelizumab）重拳出击，在复发/难治cHL中疗效突出, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fae615485275)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985299, encodeId=32b2198529967, content=<a href='/topic/show?id=186046636e' target=_blank style='color:#2F92EE;'>#cHL#</a>, objectTitle=Blood：微调FOXO3A，是cHL的一种生存机制，也是流产性浆细胞分化的标志, objectType=article, longId=129983, objectId=4bfe12998329, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4bfe12998329, replyNumber=0, likeNumber=87, createdTime=2018-02-14, rootId=0, userName=12498adam40暂无昵称, userId=f07c2500133, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4bfe12998329, moduleTitle=Blood：微调FOXO3A，是cHL的一种生存机制，也是流产性浆细胞分化的标志, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4bfe12998329)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985300, encodeId=eaba198530051, content=<a href='/topic/show?id=186046636e' target=_blank style='color:#2F92EE;'>#cHL#</a>, objectTitle=Cochlear Implants Int：耳蜗移植后面部神经刺激研究, objectType=article, longId=135020, objectId=d50e135020f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d50e135020f5, replyNumber=0, likeNumber=84, createdTime=2018-12-11, rootId=0, userName=12498adam40暂无昵称, userId=f07c2500133, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d50e135020f5, moduleTitle=Cochlear Implants Int：耳蜗移植后面部神经刺激研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d50e135020f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985298, encodeId=34ef198529861, content=<a href='/topic/show?id=186046636e' target=_blank style='color:#2F92EE;'>#cHL#</a>, objectTitle=Cochlear Implants Int：儿科耳蜗移植使用者不连续设备使用的流行度和风险因素分析, objectType=article, longId=126410, objectId=1a0a1264104b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a0a1264104b, replyNumber=0, likeNumber=65, createdTime=2018-10-25, rootId=0, userName=12498adam40暂无昵称, userId=f07c2500133, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a0a1264104b, moduleTitle=Cochlear Implants Int：儿科耳蜗移植使用者不连续设备使用的流行度和风险因素分析, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1a0a1264104b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985301, encodeId=80b6198530148, content=<a href='/topic/show?id=186046636e' target=_blank style='color:#2F92EE;'>#cHL#</a>, objectTitle=周剑峰教授：信迪利单抗在复发/难治经典型霍奇金淋巴瘤（R/R-cHL）治疗中的研究结果及临床意义, objectType=article, longId=139928, objectId=364c13992828, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=364c13992828, replyNumber=0, likeNumber=68, createdTime=2018-08-11, rootId=0, userName=12498adam40暂无昵称, userId=f07c2500133, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=364c13992828, moduleTitle=周剑峰教授：信迪利单抗在复发/难治经典型霍奇金淋巴瘤（R/R-cHL）治疗中的研究结果及临床意义, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=364c13992828)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1985297, encodeId=d1a0198529ebe, content=<a href='/topic/show?id=186046636e' target=_blank style='color:#2F92EE;'>#cHL#</a>, objectTitle=FDA授予默沙东PD-1免疫疗法Keytruda第4个突破性药物资格：经典型霍奇金淋巴瘤（cHL）, objectType=article, longId=66949, objectId=653e669497b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=653e669497b, replyNumber=0, likeNumber=77, createdTime=2016-11-20, rootId=0, userName=12498adam40暂无昵称, userId=f07c2500133, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=653e669497b, moduleTitle=FDA授予默沙东PD-1免疫疗法Keytruda第4个突破性药物资格：经典型霍奇金淋巴瘤（cHL）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=653e669497b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

cHL

2020-05-29

12498adam40暂无昵称 (审核中...)

前往app查看评论内容

#cHL#

Eur J Cancer：GLS-010 (zimberelimab)在中国复发或难治性经典霍奇金淋巴瘤(r/r-cHL)患者中的疗效和安全性

2022-07-18

12498adam40暂无昵称 (审核中...)

前往app查看评论内容

#cHL#

Clin Cancer Res：Tislelizumab（替雷利珠单抗）治疗复发/难治性经典霍奇金淋巴瘤(cHL)患者疗效和安全性。

2022-06-26

12498adam40暂无昵称 (审核中...)

前往app查看评论内容

#cHL#

Cochlear Implants Int：Baha®的听觉益处和性能改善吸引了单侧听力损失患者的植入

2021-04-26

12498adam40暂无昵称 (审核中...)

前往app查看评论内容

#cHL#

FDA批准默克的KEYTRUDA（派姆单抗），治疗复发或难治性经典霍奇金淋巴瘤（cHL）成年患者

2021-04-18

12498adam40暂无昵称 (审核中...)

前往app查看评论内容

#cHL#

Blood：派姆单抗单药治疗RRcHL可获得持久的缓解

2019-10-20

12498adam40暂无昵称 (审核中...)

前往app查看评论内容

#cHL#

Neural Regen Res：Schlager小鼠可作为视网膜表型改变的模型

2020-09-02

12498adam40暂无昵称 (审核中...)

前往app查看评论内容

#cHL#

Cochlear Implants Int：青少年人工耳蜗使用者的健康相关生活质量研究

2020-07-10

12498adam40暂无昵称 (审核中...)

前往app查看评论内容

#cHL#

Blood：阻断CTLA-4或可成为对阻断PD-1耐受的cHL患者的新治疗方向

2020-01-19

12498adam40暂无昵称 (审核中...)

前往app查看评论内容

#cHL#

PNAS：UCHL1影响脑缺血后的损伤和功能恢复

2019-09-11

12498adam40暂无昵称 (审核中...)

前往app查看评论内容

#cHL#

Lancet Haematology：重磅！中国PD-1抑制剂信迪利单抗治疗cHL关键研究荣登《柳叶刀血液病学》封面

2019-05-04

12498adam40暂无昵称 (审核中...)

前往app查看评论内容

#cHL#

PD-1抑制剂替雷利珠单抗（Tislelizumab）重拳出击，在复发/难治cHL中疗效突出

2019-04-29

12498adam40暂无昵称 (审核中...)

前往app查看评论内容

#cHL#

Blood：微调FOXO3A，是cHL的一种生存机制，也是流产性浆细胞分化的标志

2018-02-14

12498adam40暂无昵称 (审核中...)

前往app查看评论内容

#cHL#

Cochlear Implants Int：耳蜗移植后面部神经刺激研究

2018-12-11

12498adam40暂无昵称 (审核中...)

前往app查看评论内容

#cHL#

Cochlear Implants Int：儿科耳蜗移植使用者不连续设备使用的流行度和风险因素分析

2018-10-25

12498adam40暂无昵称 (审核中...)

前往app查看评论内容

#cHL#

周剑峰教授：信迪利单抗在复发/难治经典型霍奇金淋巴瘤（R/R-cHL）治疗中的研究结果及临床意义

2018-08-11

12498adam40暂无昵称 (审核中...)

前往app查看评论内容

#cHL#

FDA授予默沙东PD-1免疫疗法Keytruda第4个突破性药物资格：经典型霍奇金淋巴瘤（cHL）

2016-11-20

科室
- - 订阅+
  - 更多科室
工具
服务